Express delivery and free returns within 21 days

Thursday, July 7, 2022



Contact us 561.316.3330



Hitachi, Tohoku University and Kyoto University Become World’s First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal...

TAT is a new cancer therapy that combines a substance that emits alpha particles which destroy cancer cells with a compound that selectively accumulates in cancer cells.

Sirtex Medical & China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China

November 2020, the National Medical Products Administration (NMPA) of the People’s Republic of China accepted the Sirtex new drug application (NDA) of SIR-Spheres® Y-90 resin microspheres for the treatment of colorectal cancer liver metastases.

RefleXion Medical Expands Commercial Reach With Sale to Texas Cancer Center

Installation of the RefleXion X1 machine, which will be located at the main campus in Fort Worth, is expected to begin in early 2022.

SIROS System for Advanced SIR-Spheres® Resin Microspheres Delivery Launched

Sirtex Medical reports SIROS™ offers a visual, intuitive and versatile option for interventional radiologists to deliver SIR-Spheres® to patients with liver cancer.

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers

The aim of the clinical collaboration between RefleXion and Merck is to establish whether treating multiple tumors with BgRT, a novel external beam radiotherapy treatment modality in development is safe and amplifies KEYTRUDA’s therapeutic effect.

ViewRay Partners with Device Technologies Australia Pty Ltd.

ViewRay, Inc. will partner with the largest independent distributor in Australasia, who will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system.

By using this website you agree to accept Medical Device News Magazine Privacy Policy